Apogee Therapeutics, Inc. beat EPS estimates 67% of the time across 3 reported quarters (2 beats, 1 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-1.10 | $-1.14 | -3.6% | Miss |
| Q12026 FY2026 | $-1.12 | $-1.06 | +5.4% | Beat |
| Q42025 FY2025 | $-1.05 | $-1.03 | +1.9% | Beat |
Back to APGE overview · APGE holders · APGE KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.